Big Pharma's Shelves Fuel Biotech's Dreams
We review deals in which biotechs access Big Pharma's shelved development projects.
You may also be interested in...
A new crop of companies deals head-on with Big Pharma's biggest out-licensing problems--transaction cost and the "embarrassment factor." Solving both involves strategies to make the extra work of out-licensing worthwhile for their large partners. In particular, after years of resisting the idea, they're now allowing their Big Pharma partners the right to buy back the compounds, usually after clinical proof of concept.
ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.
A senior DHL executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world and the specific challenges and complexities involved. The company has prior experience with the “deep frozen” temperatures needed for some candidates.